Brown Advisory Inc. reduced its position in Catalent, Inc. (NYSE:CTLT – Get Rating) by 13.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,179,664 shares of the company’s stock after selling 187,745 shares during the period. Brown Advisory Inc. owned about 0.66% of Catalent worth $131,169,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Prospera Financial Services Inc purchased a new stake in shares of Catalent during the first quarter worth $33,000. Parkside Financial Bank & Trust grew its holdings in shares of Catalent by 127.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 282 shares of the company’s stock worth $36,000 after buying an additional 158 shares in the last quarter. Covestor Ltd purchased a new stake in shares of Catalent during the fourth quarter worth $39,000. Ellevest Inc. grew its holdings in shares of Catalent by 39.5% during the first quarter. Ellevest Inc. now owns 406 shares of the company’s stock worth $45,000 after buying an additional 115 shares in the last quarter. Finally, Sageworth Trust Co of South Dakota purchased a new stake in shares of Catalent during the fourth quarter worth $63,000. Hedge funds and other institutional investors own 98.05% of the company’s stock.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Catalent from $129.00 to $110.00 and set a “hold” rating for the company in a report on Tuesday, April 12th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $142.86.
Catalent Stock Up 1.1 %
Catalent (NYSE:CTLT – Get Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The company reported $1.00 EPS for the quarter, beating the consensus estimate of $0.89 by $0.11. The company had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.22 billion. Catalent had a net margin of 10.72% and a return on equity of 15.07%. The firm’s revenue was up 20.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.78 earnings per share. As a group, equities research analysts predict that Catalent, Inc. will post 3.57 earnings per share for the current fiscal year.
Insider Buying and Selling at Catalent
In other Catalent news, CEO Alessandro Maselli sold 816 shares of the stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total value of $87,230.40. Following the transaction, the chief executive officer now directly owns 25,083 shares in the company, valued at $2,681,372.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Ricky Hopson sold 312 shares of the stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total transaction of $33,352.80. Following the completion of the sale, the insider now directly owns 17,035 shares of the company’s stock, valued at $1,821,041.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Alessandro Maselli sold 816 shares of the firm’s stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total value of $87,230.40. Following the completion of the sale, the chief executive officer now directly owns 25,083 shares of the company’s stock, valued at approximately $2,681,372.70. The disclosure for this sale can be found here. Insiders have sold 4,462 shares of company stock worth $476,951 over the last three months. Insiders own 0.53% of the company’s stock.
Catalent Company Profile
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.